Table 2. Baseline Patient Characteristics .

afib: atrial fibrillation; TIA: transient ischemic attack; DM: diabetes mellitus; HTN: hypertension; CAD: coronary artery disease; CHF: congestive heart failure

	All -14	Atrial fibrillation prior to starting ibrutinib (10)	Atrial fibrillation after starting ibrutinib (4)
Gender, male	10 (71.42%)	7 (70%)	3 (75%)
Race
Caucasian	10 (71.42%)	8 (80%)	2 (50%)
Black	2 (14.29%)	1 (10%)	1 (25%)
Other	2 (14.29%)	1 (10%)	1 (25%)
Malignancy
Chronic lymphocytic leukemia	6 (42.86%)	5 (50%)	1 (25%)
Mantle cell lymphoma	7 (50%)	4 (40%)	3 (75%)
Waldenström’s macroglobulinemia	1 (7.14%)	1 (10%)	0
Atrial fibrillation	14	10	4
Starting dose of ibrutinib – mean	430 mg	569 mg	420 mg, onset of afib within a year: 4 (100%)
Co-morbid conditions
Age (mean) at time of atrial fibrillation and ibrutinib	68.23	65.77	73.75
Prior history of stroke or TIA	0	0	0
Vascular disease	0	0	0
DM	3 (21.43%)	1 (10%)	2 (50%)
HTN	11 (78.57%)	7 (70%)	4 (100%)
CAD	6 42.86%)	6 (60%)	0
CHF	3 (21.43%)	3 (30%)	0
Renal dysfunction	3 (21.43%)	2 (20%)	1 (25%)
Thyrotoxicosis	0	0	0
Alcohol abuse	0	0	0
Smoking	5 (35.71%)	4 (40%)	1 (25%)
Chronic liver disease	0	0	0
Chronic lung disease	3 (21.43%)	2 (20%)	1 (25%)
Substance abuse	0	0	0